Moderna Pivots to Cancer Treatments After Landmark Melanoma Trial Results

Cambridge, Thursday, 12 November 2026.
Moderna is expanding production after Phase 3 data showed its experimental personalized cancer therapy cut the risk of melanoma recurrence or death by 42% when combined with existing immunotherapy.